Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: A randomised clinical trial

British Journal of Ophthalmology

Volumn 97, Issue 7, 2013, Pages 885-889

  Preti, Rony Carlos ^a   Ramirez, Lisa Mariel Vasquez ^a   Monteiro, Mario Luiz Ribeiro ^a   Carra, Mario Kehdi ^a   Pelayes, David E ^b,c   Takahashi, Walter Yukihiko ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c DEPARTAMENTO DE CIENCIAS NATURALES Y ANTROPOLOGÍA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTRAST SENSITIVITY; CONTROLLED STUDY; DETERIORATION; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; FEMALE; FOLLOW UP; HIGH RISK PROLIFERATIVE DIABETIC RETINOPATHY; HUMAN; LASER COAGULATION; LENS; MALE; NEODYMIUM YAG LASER; OPHTHALMOLOGICAL SURGICAL EQUIPMENT; PANRETINAL PHOTOCOAGULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VISUAL ACUITY; VITREOUS HEMORRHAGE;

ANGIOGENESIS; RETINA; TREATMENT LASERS; TREATMENT MEDICAL; VISUAL PERCEPTION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; CONTRAST SENSITIVITY; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84879422393     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2012-302675     Document Type: Article

References (24)

1. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology 1991;98(5 Suppl):741-56.
2. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 1991;98(5 Suppl):766-85.
3. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology 1981;88:583-600.
4. McDonald HR, Schatz H. Macular edema following panretinal photocoagulation. Retina 1985;5:5-10.
5. Marmor MF. Contrast sensitivity versus visual acuity in retinal disease. Br J Ophthalmol 1986;70:553-9.
6. Arden GB. The importance of measuring contrast sensitivity in cases of visual disturbance. Br J Ophthalmol 1978;62:198-209.
7. Sokol S, Moskowitz A, Skarf B, et al. Contrast sensitivity in diabetics with and without background retinopathy. Arch Ophthalmol 1985;103:51-4.
8. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
9. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010;117:1078-86 e2.
10. Tonello M, Costa RA, Almeida FP, et al. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol 2008;86:385-9.
11. Mirshahi A, Roohipoor R, Lashay A, et al. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur J Ophthalmol 2008;18:263-9.
12. Mason JO III, Yunker JJ, Vail R, et al. Intravitreal bevacizumab (Avastin) prevention of panretinal photocoagulation-induced complications in patients with severe proliferative diabetic retinopathy. Retina 2008;28:1319-24.
13. Aiello LP, Edwards AR, Beck RW, et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2010;117:946-53.
14. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98(5 Suppl):807-22.
15. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina 2004;24(5 Suppl):S3-19.
16. The Early Treatment Diabetic Retinopathy Study Research Group. Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report no. 3. Int Ophthalmol Clin 1987;27:254-64.
17. Olk RJ. Modified grid argon (blue-green) laser photocoagulation for diffuse diabetic macular edema. Ophthalmology 1986;93:938-50.
18. Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-806.
19. Mackie SW, Walsh G. Contrast and glare sensitivity in diabetic patients with and without pan-retinal photocoagulation. Ophthalmic Physiol Opt 1998;18:173-81.
20. Khosla PK, Rao V, Tewari HK, et al. Contrast sensitivity in diabetic retinopathy after panretinal photocoagulation. Ophthalmic Surg 1994;25:516-20.
21. Canning C, Polkinghorne P, Ariffin A, et al. Panretinal laser photocoagulation for proliferative diabetic retinopathy: the effect of laser wavelength on macular function. Br J Ophthalmol 1991;75:608-10.
22. Otani T, Yamaguchi Y, Kishi S. Correlation between visual acuity and foveal microstructural changes in diabetic macular edema. Retina 2010;30:774-80.
23. Arend O, Remky A, Evans D, et al. Contrast sensitivity loss is coupled with capillary dropout in patients with diabetes. Invest Ophthalmol Vis Sci 1997;38:1819-24.
24. Conrath J, Giorgi R, Raccah D, et al. Foveal avascular zone in diabetic retinopathy: quantitative vs qualitative assessment. Eye (Lond) 2005;19:322-6.